Olaparib Plus Vistusertib Promising in Early Trial

June 8, 2018 9:48 pm

The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504Read more

PFS Rises in Ovarian Cancer with Repeat Bevacizumab

June 8, 2018 9:47 pm

Women with advanced ovarian cancer previously treated with bevacizumab (Avastin) had a 3-month improvement in progression-free survival (PFS) when they received second-line therapy that included bevacizumab, European investigators reported.

Median PFS increased from 8.8 months with platinum-based chemotherapy to 11.8 … Read more

Pembrolizumab Monotherapy Shows Activity in Advanced Recurrent OC

June 7, 2018 9:52 pm

Pembrolizumab monotherapy is associated with antitumor activity in patients with advanced recurrent ovarian cancer, interim results from the phase 2 KEYNOTE-100 study suggest.

Notably, objective response rates among study subjects increased in tandem with increased programmed death-ligand 1 (PD-L1) expression, … Read more

Non-Chemo Combo Active in Ovarian Cancer

June 6, 2018 7:00 pm

The combination of two targeted agents – the PARP inhibitor niraparib (Zejula) plus the checkpoint inhibitor pembrolizumab (Keytruda) — appears to elicit a durable response among women with heavily pretreated, refractory ovarian cancer, researchers reported here.

About 25% of women … Read more

Is Adjuvant Chemo Warranted In Stage I Ovarian Clear Cell Carcinoma?

May 31, 2018 7:11 pm

In patients with stage I ovarian clear cell carcinoma, the use of adjuvant chemotherapy was associated with superior overall survival (OS), according to results of a large, retrospective cohort study.

The finding, published in Gynecologic Oncology, provides further evidence … Read more

Scientists Identify Why Some May Be Resistant To PARP Inhibitor Drugs

May 21, 2018 6:33 pm

A team of scientists from the Institute of Cancer Research in London has identified DNA mutations which makes cancer cells resistant to a new class of drugs called PARP inhibitors, used for the treatment of breast and ovarian cancers.

The … Read more

‘Personalized’ Ovarian CA Vaccine May Prolong Survival

April 16, 2018 9:42 pm

A novel cancer vaccine made from autologous whole-tumor and dendritic cells significantly improved survival in women with recurrent advanced epithelial ovarian cancer (EOC), given alone or in combination with standard immunomodulatory therapy, researchers found.

An international pilot study in 25 … Read more

New Immunotherapy Shows Promise Against Ovarian Cancer

April 10, 2018 8:57 pm

Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.

One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more

FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

April 2, 2018 5:19 pm

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more

SGO 2018: Putting PARP Inhibitor Perspectives Into Practice

March 28, 2018 9:28 pm

Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more

SGO 2018: A Vaccine Shows Promise Against Ovarian Cancer

March 26, 2018 9:11 pm

A vaccine derived from a patient’s tumor cells, which enhances T-cell targeting of cancer cells, has shown promise against ovarian cancer.

This outcome of a phase 1 clinical trial was reported at the Society of Gynecologic Oncology’s 2018 Annual Meeting … Read more

Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were Wrong.

February 21, 2018 7:16 pm

No one expected the four young women to live much longer. They had an extremely rare, aggressive and fatal form of ovarian cancer. There was no standard treatment.

The women, strangers to one another living in different countries, asked their … Read more

Clinical Trials Offer Promising New Treatments for Ovarian Cancer

February 5, 2018 9:10 pm

By: Deborah Zajchowski, PhD – Scientific Director, The Clearity Foundation

In the past three years, new hope has come to many women with ovarian cancer because of four new drugs that were approved for the treatment of this disease. These … Read more

BRCA1 Methylation Tied to Ovarian Cancer Risk

January 18, 2018 4:26 am

BRCA1 mutations are well-known to predispose to ovarian cancer risk. But now a new study, appearing in the Annals of Internal Medicine, suggests that methylation of normal BRCA1 genes might be a major ovarian cancer risk factor. In this Read more

Heated Abdominal Chemo Bath Improves Ovarian Cancer Survival

January 17, 2018 5:00 pm

By Gene Emery

A heated chemotherapy organ bath circulated throughout the abdomen after surgery can significantly prolong a woman’s survival with advanced ovarian cancer, according to doctors testing the new treatment.

Patients who underwent the experimental procedure at 8 hospitals … Read more

Women with Ovarian Cancer Who May Benefit from Maintenance Treatment

January 15, 2018 6:18 pm

Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).

Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more

Combinations May Be The Future Of Immunotherapy In Ovarian Cancer

January 12, 2018 10:27 pm

To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can … Read more

FDA Grants Priority Review for Rucaparib

December 28, 2017 8:08 pm

The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more

Future Focus: Ovarian Cancer in 2018 and Beyond

December 14, 2017 3:49 pm

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further … Read more